• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

Antitumor activity of nab-sirolimus versus mTOR inhibitors temsirolimus, sirolimus, and everolimus in A549 NSCLC xenografts
Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Patients With Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Institutional experience with nab-sirolimus in patients with malignancies harboring TSC1 or TSC2 mutations
Aadi Bioscience Presents Emerging Data for FYARRO™ in Patients with Solid Tumors Harboring TSC1 or TSC2 Inactivating Alterations from a Multi-Institution Expanded Access Program at ASCO 2021
Aadi Bioscience Receives Breakthrough Therapy Designation for ABI-009 in PEComa Indication
Aadi Bioscience Recieves FDA’ Orphan Product Development Grant for Treatment of Advanced PEComa
Baiteng Zhao, PhD

Comments

Comments are closed.

  • Next Post
  • Previous Post